1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
2
|
Guadagni S, Catarci M, Kinoshita T,
Valenti M, De Bernardinis G and Carboni M: Causes of death and
recurrence after surgery for early gastric cancer. World J Surg.
21:434–439. 1997.PubMed/NCBI View Article : Google Scholar
|
3
|
Ahn JB, Ha TK and Kwon SJ: Bone metastasis
in gastric cancer patients. J Gastric Cancer. 11:38–45.
2011.PubMed/NCBI View Article : Google Scholar
|
4
|
Park HS, Rha SY, Kim HS, Hyung WJ, Park
JS, Chung HC, Noh SH and Jeung HC: A prognostic model to predict
clinical outcome in gastric cancer patients with bone metastasis.
Oncology. 80:142–150. 2011.PubMed/NCBI View Article : Google Scholar
|
5
|
Silvestris N, Pantano F, Ibrahim T,
Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo
A, Febbraro A, et al: Natural history of malignant bone disease in
gastric cancer: Final results of a multicenter bone metastasis
survey. PLoS One. 8(e74402)2013.PubMed/NCBI View Article : Google Scholar
|
6
|
Turkoz FP, Solak M, Kilickap S, Ulas A,
Esbah O, Oksuzoglu B and Yalcin S: Bone metastasis from gastric
cancer: The incidence, clinicopathological features, and influence
on survival. J Gastric Cancer. 14:164–172. 2014.PubMed/NCBI View Article : Google Scholar
|
7
|
Kim YJ, Kim SH, Kim JW, Lee JO, Kim JH,
Bang SM, Lee JS and Lee KW: Gastric cancer with initial bone
metastasis: A distinct group of diseases with poor prognosis. Eur J
Cancer. 50:2810–2821. 2014.PubMed/NCBI View Article : Google Scholar
|
8
|
Nishidoi H and Koga S: Clinicopathological
study of gastric cancer with bone metastasis. Gan To Kagaku Ryoho.
14:1717–1722. 1987.PubMed/NCBI(In Japanese).
|
9
|
Choi CW, Lee DS, Chung JK, Lee MC, Kim NK,
Choi KW and Koh CS: Evaluation of bone metastases by Tc-99m MDP
imaging in patients with stomach cancer. Clin Nucl Med. 20:310–314.
1995.PubMed/NCBI View Article : Google Scholar
|
10
|
Nielsen OS, Munro AJ and Tannock IF: Bone
metastases: Pathophysiology and management policy. J Clin Oncol.
9:509–524. 1991.PubMed/NCBI View Article : Google Scholar
|
11
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002.PubMed/NCBI View
Article : Google Scholar
|
12
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12 (Suppl)(6243S-6249S)2006.PubMed/NCBI View Article : Google Scholar
|
13
|
Berenson JR, Rosen LS, Howell A, Porter L,
Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A and Seaman JJ:
Zoledronic acid reduces skeletal-related events in patients with
osteolytic metastases. Cancer. 91:1191–1200. 2001.PubMed/NCBI View Article : Google Scholar
|
14
|
Riihimaki M, Hemminki A, Sundquist K,
Sundquist J and Hemminki K: Metastatic spread in patients with
gastric cancer. Oncotarget. 7:52307–52316. 2016.PubMed/NCBI View Article : Google Scholar
|
15
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001.PubMed/NCBI View Article : Google Scholar
|
16
|
Lim SM, Kim YN, Park KH, Kang B, Chon HJ,
Kim C, Kim JH and Rha SY: Bone alkaline phosphatase as a surrogate
marker of bone metastasis in gastric cancer patients. BMC Cancer.
16(385)2016.PubMed/NCBI View Article : Google Scholar
|
17
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 Study
Group. J Clin Oncol. 24:4991–4997. 2006.PubMed/NCBI View Article : Google Scholar
|
18
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008.PubMed/NCBI View Article : Google Scholar
|
19
|
Kang JH, Lee SI, Lim DH, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012.PubMed/NCBI View Article : Google Scholar
|
20
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, et al: Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): An
open-label, phase 3 randomised controlled trial. Lancet Oncol.
15:78–86. 2014. View Article : Google Scholar
|
21
|
Mikami J, Kimura Y, Makari Y, Fujita J,
Kishimoto T, Sawada G, Nakahira S, Nakata K, Tsujie M and Ohzato H:
Clinical outcomes and prognostic factors for gastric cancer
patients with bone metastasis. World J Surg Oncol. 15(8)2017.
View Article : Google Scholar
|
22
|
Rosen LS, Gordon D, Kaminski M, Howell A,
Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma
DJ, et al: Long-term efficacy and safety of zoledronic acid
compared with pamidronate disodium in the treatment of skeletal
complications in patients with advanced multiple myeloma or breast
carcinoma: A randomized, double-blind, multicenter, comparative
trial. Cancer. 98:1735–1744. 2003.PubMed/NCBI View Article : Google Scholar
|
23
|
Fizazi K, Carducci M, Smith M, Damiao R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011.PubMed/NCBI View Article : Google Scholar
|
24
|
Stopeck AT, Lipton A, Body JJ, Steger GG,
Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA,
Viniegra M, et al: Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast
cancer: A randomized, double-blind study. J Clin Oncol.
28:5132–5139. 2010.PubMed/NCBI View Article : Google Scholar
|